FreeTheAI

Oncolytics Biotech Sets GOBLET Trial Data Timeline and Expects Final Grant Payment

BullishMedium impact
ONCY$0.4686 −4.37%

Oncolytics Biotech Inc. (ONCY) has outlined the timing for upcoming clinical data readouts from its ongoing GOBLET study. The company anticipates sharing final results from Cohort 4 during the fourth quarter of 2026. Initial results for Cohort 5 are expected in the first half of 2027.

With trial enrollment now finished, Oncolytics Biotech Inc. is winding down clinical infrastructure for the study, which will help lower ongoing trial operating expenses. The trial cohorts previously met pre-established efficacy criteria. Additionally, the company expects to receive its final grant payment from PanCAN later this quarter, providing non-dilutive funding.

Investors will be monitoring the upcoming fourth-quarter Cohort 4 results and the subsequent Cohort 5 readout in 2027 for insights into treatment efficacy and future strategic planning. Following the update, Oncolytics Biotech Inc. stock rose 3.53% to $0.49.

Key points

  • Final results from Cohort 4 of the GOBLET trial are expected in the fourth quarter of 2026.
  • Initial data from Cohort 5 are scheduled for release in the first half of 2027.
  • Trial enrollment is complete, allowing the company to wind down trial infrastructure and reduce operating expenses.
  • Oncolytics Biotech Inc. expects to receive its final PanCAN grant payment later in the current quarter.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

When will Oncolytics Biotech release GOBLET Cohort 4 data?

Oncolytics Biotech expects to publish final results for Cohort 4 of the GOBLET study in the fourth quarter of 2026.

When are initial results for GOBLET Cohort 5 expected?

Initial data for Cohort 5 are scheduled to be released in the first half of 2027.

Is Oncolytics Biotech receiving additional funding soon?

The company expects to receive its final PanCAN grant payment later in the current quarter, providing non-dilutive capital.